In Europe, the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) follows a multimodal approach that integrates pharmacological and non-pharmacological interventions. As of early 2026, clinical guidelines across the continent emphasize a personalized care pathway, where medication is often combined with psychoeducation, behavioral therapy, and environmental adjustments. Stimulants, particularly methylphenidate, remain the most common first-line pharmacological choice, with newer options like lisdexamfetamine and guanfacine seeing increased uptake. While the UK and Germany have seen a sharp rise in adult diagnoses and prescriptions—especially among women—other countries like Spain and the Netherlands focus heavily on rigorous diagnostic evaluations to ensure treatment adequacy. Non-pharmacological treatments, such as Cognitive Behavioral Therapy (CBT) and parental training programs, are highly encouraged to manage lifelong symptoms. Despite the growing recognition of ADHD as a chronic condition, many European health systems are currently navigating medication shortages and a push for more integrated care models to address the rising demand among the adult population.